the ligand for Fas antigen (FasL) is constitutively expressed on thyroid follicular cells from both normal and Hashimoto's thyroiditis (HT) tissue, and that normal thyrocytes express Fas antigen only after induction with interleukin-1␤ (IL-1␤). Giordano et al. conclude that their results suggested a possible mechanism for thyrocyte cytotoxicity in autoimmune thyroiditis. The absence of Fas antigen expression on the surface of normal thyrocytes has been supported by one study (2) ; however, other studies have found Fas expression by normal thyrocytes both in situ (3) and in primary cultured cells (4, 5) . The findings by Giordano et al. raised the possibility of the expression of both Fas antigen and FasL on normal thyrocytes. To clarify this issue, we examined the expression of both FasL and Fas antigen mRNA in primary cultured thyrocytes with the use of reversetranscriptase polymerase chain reaction (RT-PCR) (6) and ribonuclease protection (7) techniques. Neither assay, performed on RNA isolated from normal human thyrocytes, demonstrated mRNA for FasL (Fig. 1 , A and B). To assure that this result was not unique to this sample, RNA samples from five different normal and Graves's diseased thyrocytes were screened by ribonuclease protection assay; these also did not show mRNA for FasL (Fig. 1C) . In contrast, Fas antigen mRNA was detected in all five specimens ( Fig. 1C ) and has also been detected by RT-PCR (5) . Treating the thyroid cells with TSH, IL-1␤, or ␥INF for up to 48 hours (before harvest and RNA isolation) also did not induce the expression of FasL mRNA or alter the expression of Fas antigen mRNA.
We also examined the expression of FasL protein in thyroid follicular cells with the use of immunohistochemical staining (8) and Western blotting (9) techniques similar to those employed by Giordano et al. (1) . Immunostaining of normal thyrocytes with a polyclonal, rabbit antibody to FasL did not detect FasL protein (10), but, consistent with the other studies, these cells demonstrated significant amounts of Fas antigen staining (2) (3) (4) . Unexpectedly, a protein immunoblot of thyroid cell lysates performed with the mouse monoclonal antibody used by Giordano et al. (clone 33, Transduction Laboratories, Lexington, Kentucky) yielded an intense band at the appropriate size for FasL (Fig. 2) . However, there was no difference in intensity of this band in lysates of PMA stimulated as opposed to untreated Jurkat cells, and this finding did not correlate with the changes in mRNA concentration observed in these cells (Fig. 1, A and B) . This result brings into question the specificity of the clone 33 antibody for FasL.
Although there may be differences in the tissues examined by ourselves and Giordano et al., we have not observed the expression of mRNA for FasL in primary cultured thyrocytes from over 20 normal and thyroiditis tissue samples, unless there was also evidence of mRNA for rearranged immunoglobulin genes (10). The latter result suggests that, in those situations, the message for FasL came from lymphocyte contamination of the thyroid cells. More importantly, FasL-induced programmed cell death in thyroiditis is questioned by our recent finding that the Fas pathway in thyroid follicular cells is blocked by a labile protein inhibitor (5) . It has also been found that the in vitro induction of the Fas pathway with soluble ligand or antibody may be less efficient than that achieved by cytotoxic T cells (11). Together, these considerations make it difficult to predict the relative importance of Fas-mediated apoptosis in thyroiditis. We hope that the findings presented in this comment will promote the research and discussion necessary to clarify the potential role of the Fas pathway in the pathogenesis of thyroiditis.
Theophil A. Stokes After the final cycle, the temperature was held at 72°C for 10 min to allow re-annealing of the amplified products. PCR products were then size-fractionated through a 2% agarose gel and the bands visualized with the use of ethidium bromide. A pair of primers was used to amplify human ␤-actin as a control. Primer sequences: FasL: forward primer: 5Ј-ACAACCTGCCCCTGAGCC-3Ј; reverse primer: 5Ј-AGTCT TCCT T T TCCATCCC-3Ј; ␤-actin: forward primer: 5Ј-CACGGCAT TGTAACCAACTG-3Ј; reverse primer: 5Ј-TCTCAGCTGTGGTGGTGAAG-3Ј. 7. For ribonuclease (RNase) protection, the RiboQuant MultiProbe RNase Protection Assay System (Pharmingen, San Diego, CA) was used for the detection and quantitation of specific mRNA species.
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P-labeled antisense RNA probes were prepared with the use of the Human Apoptosis hAPO-3 Template Set (Pharmingen), which included Fas, FasL, and human glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Probes were hybridized with 10 g of RNA from treated thyrocytes, Jurkat cells, and peripheral blood lymphocytes. After hybridization, samples were subjected to RNase treatment followed by purification of RNase-protected probes. Protected probes were resolved on a 5% denaturing polyacrylamide gel. 8. Thyroid cells were grown on Falcon chamber slides (Becton Dickinson, Franklin Lanes, NJ) or on glass coverslips. For immunostaining, slides were washed twice with PBS, then fixed with methanol for 5 min at 4°C, briefly air-dried, placed into PBS and blocked with 5% normal goat serum. Slides were incubated with 1.0 g/ ml affinity purified rabbit antibody to Fas (C-20, Santa Cruz Biotechnology), antibody to FasL (Q-20, Santa Cruz Biotechnology), or rabbit antithyroglobulin (Dako Corp., Carpinteria, CA). After washing with PBS, slides were incubated with biotinylated Abs specific for rabbit IgG, followed by detection using an avidin-biotin complex detection kit with glucose oxidase substrate ( Vectastain ABC-GO kit, Vector Labs., Burlingame, CA). Slides were briefly counterstained with eosin and mounted with permount (Fisher Scientific, Fair Lawn, NJ). 9. Thyrocytes were scraped from tissue culture dishes and collected by centrifugation at 200 g for 10 min. Cell pellets were lysed in cold lysis buffer (0.5% Triton X-100 in 50 mM tris, pH 7.6, 300 mM NaCl) containing protease inhibitors for 30 min on ice, then centrifuged at 15,000g for 20 min, and the Triton-soluble protein fraction was collected. Total protein concentrations were determined using BCA protein assay (Pierce Chemicals, Rockford, IL). As a positive control for expression of FasL, protein lysates were also prepared from Jurkat cells that were activated using PMA and ionomycin for 4 hours. Equal amounts of cell protein lysates were mixed with 2X sample buffer (4% SDS, 10% ␤-mercaptoethanol, 20% glycerol in 0.125 M tris, pH 6.8), samples were boiled for 3 min, then separated by electrophoresis on a 12.5% SDS-polyacrylamide gel. Proteins were then electrophoretically transferred to nitrocellulose. Blots were first blocked in 5% milk in PBS with 0.02% sodium azide (PBS-A) for 2 hours at 25°C. Blots were incubated overnight at 4°C with mouse monoclonal anti-FasL (Clone 33, Transduction Laboratories, Lexington, KY ).
After washing with PBS with 0.02% sodium azide and 0.05% Tween-20 (PTA), blots were then incubated with anti-mouse IgG alkaline phosphatase conjugated antibody (both from Jackson ImmunoResearch Labs., West Grove, PA) diluted 1: 2500 in 5% milk/PBS-A for 1 to 2 hours at 25°C. 
With the use of monoclonal antibody 33 (mAb33), we analyzed FasL expression with protein immunoblots in a panel of human tumor cell lines covering different B cell, monocyte, and T cell lines. Unexpectedly, we found that all these cell lines express FasL, as shown by a single band on the blot at about 37 kD. To confirm these results, we tested these cell lysates with a FasL-specific rabbit polyclonal antiserum PE62 against an extracellular peptide of FasL (2) . In contrast to the results obtained with mAb33, none of these cell lines now showed a FasL-specific signal (Fig. 1A) .
We therefore examined further the FasL specificity of mAb33. We transiently transfected human 293T embryonic kidney carcinoma cells with a FasL expression vector that encodes human FasL that has an NH 2 -terminal FLAG tag, and we performed a protein immunoblot, with the use of the FasL-specific antibodies mAb33, C-20, G247-4 (Pharmingen), and P62 (2), as well as M2 (Eastman Kodak, New Haven, Connecticut), which is specific for the NH 2 -terminal FLAG tag (Fig. 1B) .
With the use of mAbs C247-4 and M2, the FasL-transfected 293T cells showed FasL-specific signals that were absent in the untransfected control cells. Although the polyclonal rabbit antibodies C-20 and PE62 showed some background staining in untransfected 293T cells, they also revealed CD95L-specific signals in the lysates of the transfectants, as would be expected from earlier reports (2-4). In contrast, mAb33 detected a 37-kD signal (similar to the band in Fig. 1A ) in both transfected and untransfected cells. To further characterize the specificity of mAb33, we immunoprecipitated FLAG-tagged FasL from lysates of transfected 293T cells with the use of the FLAGspecific antibody M2. The immunoprecipitates were tested by protein immunoblotting with G247-4 and mAb33. FasL expression was detected with G247-4, but not with mAb33. However, mA33 (but not G247-4) produced a strong 37-kD signal in the supernatant of the immunoprecipitate (Fig. 1C) .
Thus, C-20, PE62, and G247-4-but not mAb33-seem to be suited for the analysis of CD95L expression by protein immunoblotting. However, mAb33 does not stain human FasL, but a different protein expressed in many cell types. It is therefore questionable whether the signals shown in figure 4 of the report by Giordano et al. correspond to FasL expressed by thyroid cells.
With the use of 293T cells transfected with FLAG-tagged FasL, we then analysed several antibodies (NOK-1, NOK-2 (5), and G247-4 (PharmIngen, San Diego, California), mAb33, C-20, and MIKE 2 (Alexis, San Diego, California) for FasL specific staining with the use of flow cytometry and immunoflorescence. Untransfected cells served as specificity controls. With the use of a fluorescent activated cell sorter (FACS), only NOK-1, NOK-2, and MIKE-2 detected FasL expressed on the 293T cell transfectants, whereas C-20, mAb33, and G247-4 did not show any specific signals (6) . G247-4 is known to work only in Western blots, but C-20 was also reported by Giordano et al. to stain FasLexpressing thyrocytes with the use of flow cytometrical and immunohistochemical analyses. In the immunoflurescence studies, FasL-specific signals were easily detected with NOK-1, G247-4, and with the FLAGspecific antibody M2. The peptide-specific rabbit polyclonal antibody C-20, however, gave a high background staining already with untransfected cells. FasL transfectants showed stronger signals, but also a similar background staining similar to the controls. Both stainings were not seen when the blocking peptide was added (6) .
On the basis of these results, we conclude that C-20 is suited for analyzing CD95L expression by protein immunoblotting, but not by flow cytrometry, immunofluorescence, or immunohistochemistry. Because C-20 detects in such blots a signal of about 65 kD, which does not correspond to FasL (Fig. 1B) , it may also stain by immunofluorescence antigens unrelated to FasL that may bear epitopes similar to the peptide used to generate the antibody. Flow cytometrical experiments using C-20 may also reveal cells expressing such epitopes that may be absent in 293 T cells but not in thyroid cells. We therefore cannot recommend the application of C-20 in flow cytrometrical and immunofluorescence studies designed to show FasL expression.
In comparison to the other FasL-specific antibodies, mAb33 detects a different intracellular protein that seems to be expressed ubiquitously. Previous studies that used this antibody should be interpreted with caution. In conclusion, our studies describe a panel of antibodies that are specific for FasL and that may be used either in flow cytrometrical, immunofluorescence, or Western blot analysis. They also show that the two antibodies C-20 and mAb33 may bear additional specificities or might not be specific for FasL. Because both antibodies are commercially available, they seem to be used frequently by many investigators. We suggest that results from such studies (1, 7) should be reinterpreted keeping in mind the specificity of these antibodies, or repeated with the use of reagents that are known to be specific for FasL.
Petra (1) . With regard to detecting FasL in primary thyrocyte cultures with RNA protection assay and PCR, such detection would be difficult if the thyrocytes were not freshly excised and immediately analyzed, because FasL expression is labile ex vivo (mRNA or protein).
Concerning Fas expression, Stokes et al. used thyrocytes from controlateral lobes of thyroid cancers as their "normal" controls (2). We also observed variable Fas expression in uninvolved thyrocytes from thyroids with cancer, but we did not use such samples for normal controls. We obtained more normal samples from thyroid sections from patients undergoing laringectomy for laringeal cancer. These thyrocytes consistently expressed very low amounts of Fas, similar to thyrocytes from patients with nontoxic goiters (NTG), which we used in our report (1) .
Prompted by concerns raised about the specificity of the polyclonal antibody to FasL C20 (Santa Cruz, Biotechnology, Santa Cruz, California) and mAb 33 (Transduction Laboratories, Lexington, Kentucky) (see below), we repeated an immunohistochemical study with the NOK-2 antibody (PharMingen, San Diego, California) on thyroid sections from laringectomy patients (above). Most thyrocytes from normal thyroids showed detectable FasL expression (3) (Fig. 1) . In situ hybridization would further address this issue. Moreover, FACS analysis 
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Finally, (i) thyroid tissue from patients with a laringectomy or NTG and (ii) hematopoietic cell-depleted thyrocytes from patients with NTG expressed FasL, as detected by Western blot analysis with 33 mAb (Transduction Laboratories) or with G247-4 mAb (PharMingen) (Fig. 2B ). We detect a single band in our blots, similar to some investigators (4), while others detect multiple bands, which might represent glycosylated and unglycosylated forms (5).
Although we agree that C20 antibody may give a relatively high background signal as compared with other commercially available reagents, these new data support our earlier conclusion that normal thyrocytes express substantial amounts of FasL in vivo.
Fiedler et al. conclude that mAb 33 recognizes a protein different from FasL. We performed similar experiments with the use of three different cellular systems: (i) 293T cells transiently transfected with human FasL, (ii) COS-7 cells transiently transfected with human FasL (6), and (iii) NIH 3T3 stably transfected with murine FasL (7). To detect the expression of FasL by FACS analysis, we used NOK-1 mAb (PharMingen), C20, G247-4 mAb, and 33 mAb. Species and isotype-matched antibodies were used as control primary reagents. All of these antibodies gave a specific staining only in transfected cells ( Fig. 3; NIH 3T3 stably transfected with murine FasL. To reveal FasL, we used mAb 33 and mAb G247-4. Both mAbs detected an ϳ37 kD band only in transfected cells (Fig. 4) and in PMA-treated, but not in PMA-untreated, Jurkat cells (8) .
Fielder et al. find a uniform strong band reactive with the mAb 33 by protein immunoblot analysis in untransfected murine 293T cells, as well as in other human cell lines. As we detect mAb 33-reactive signals in transfected cells or in Jurkat only after PMA exposure, their finding is intriguing, and we have no explanation for it.
In conclusion, we find evidence that mAb 33 does recognize FasL in three different cell types, transiently or stably transfected with human or murine FasL, both by FACS and protein immunoblot analysis. Nevertheless, because of possible differences in specificity among the various available antibodies, we recommend the simultaneous use of several anti-FasL reagents. Constitutive FasL expression on in vivo and ex vivo normal thyrocytes has now been described by five different antibodies against FasL.
